The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Unmet needs in front-line therapy for patients with FLT3-mutated AML
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, discusses the unmet needs in front-line therapies for patients with FLT3-mutated acute myeloid leukemia (AML). Key areas for improvement include increasing remission rates and facilitating transplants for younger patients. For older patients, the standard treatments—azacitidine or decitabine plus venetoclax—are less effective against FLT3-mutated AML, making remission more challenging to achieve. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting/advisory: Rigel, Remix, Astellas, Gilead, Pfizer, Genetech, AstraZeneca, Syndax, Takeda, Schrodinger, Servier, Abbvie, BMS, Prelude; Clinical trial support: BMS, Servier, Abbvie.
